The products
TTP has been involved in the development of 25 inhalation devices over the years. This accounts for around a quarter of the world’s inhalation devices, including pressurized metered dose inhalers, dry powder inhalers and liquid aerosol devices.

These developments have been completed in partnership with clients ranging from top 10 pharmaceutical companies, to VC funded start ups.

Examples of devices in the public domain include: IVAX Airmax™, Hovione TwinCaps™ and FlowCaps™, Miat Taunus™, Clinical Designs K-Haler, Pari eFlow™, Clinical designs Helix™ pMDI dose counter, and the IVAX Easibreath™ devices.

TTP’s role

TTP’s role ranges from late stage trouble shooting, to turn key developments of multi-dose platform technologies for major pharmaceutical companies. Areas of particular expertise include:

  • Reliability engineering and probabilistic design
  • User-centred design (operation sequence, ergonomics)
  • Design for high-volume manufacture, and scale-up (DFMA)
  • Risk assessment, control and management
  • Technology audits and device appraisals
  • Design control and documentation (NDA and sNDA)
  • Complex multi physics modelling, including powder flow
  • Business case development (for structuring and negotiation licence deals)
     

What makes us different?

When TTP developed the K-Haler device, they created the first ever product to offer breath actuation, with a bill of materials close to a standard pressurised metered dose inhaler (PMDI). TTP put together an external supply chain on behalf of the client and brought the manufactured product to market.

  • Provided a modern replacement to the standard PMDI, offering prescribers and patients the benefits of breath actuation at comparable prices
  • Breath actuated technology is particularly good for young or elderly asthma patients – it is easier to use and more effective than standard PMDI technology
  • Added environmental benefits because K-Haler is made entirely from recyclable plastic.